Jacobson & Schmitt Advisors LLC Sells 6,794 Shares of IDEXX Laboratories, Inc. $IDXX

Jacobson & Schmitt Advisors LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,105 shares of the company’s stock after selling 6,794 shares during the quarter. IDEXX Laboratories accounts for about 2.2% of Jacobson & Schmitt Advisors LLC’s investment portfolio, making the stock its 24th largest holding. Jacobson & Schmitt Advisors LLC’s holdings in IDEXX Laboratories were worth $12,845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of IDXX. Counterpoint Mutual Funds LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $323,000. Mufg Securities Americas Inc. raised its holdings in IDEXX Laboratories by 21.1% during the 3rd quarter. Mufg Securities Americas Inc. now owns 2,158 shares of the company’s stock valued at $1,379,000 after buying an additional 376 shares during the last quarter. Compound Planning Inc. raised its holdings in IDEXX Laboratories by 80.2% during the 3rd quarter. Compound Planning Inc. now owns 1,186 shares of the company’s stock valued at $758,000 after buying an additional 528 shares during the last quarter. Dakota Wealth Management boosted its position in IDEXX Laboratories by 90.4% during the 3rd quarter. Dakota Wealth Management now owns 4,243 shares of the company’s stock valued at $2,711,000 after buying an additional 2,015 shares during the period. Finally, Stonebrook Private Inc. bought a new stake in IDEXX Laboratories in the 3rd quarter worth $222,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 4.2%

IDXX stock opened at $649.35 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a market capitalization of $51.70 billion, a price-to-earnings ratio of 49.68, a price-to-earnings-growth ratio of 3.79 and a beta of 1.67. The business’s 50 day moving average price is $675.31 and its two-hundred day moving average price is $669.07. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of several recent analyst reports. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. BTIG Research reduced their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This represents a 53.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 18,180 shares of company stock valued at $11,626,996 in the last three months. 0.98% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.